



Clinical Development in Multiple Sclerosis Diagnosis and Treatment

Guest Editor:

Dr. Majid Ghareghani

Neuroscience Laboratory, CHU
de Québec Research Centre,
Department of Molecular
Medicine, Faculty of Medicine,
Laval University, Québec City, QC
G1V 4G2, Canada

Deadline for manuscript
submissions:
closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that continues to challenge clinicians and researchers alike. Recent years have seen a surge in our understanding of the pathogenesis and treatment options for MS, yet there is still much to be uncovered. The application of humoral, clinical, or digital biomarkers to detect early onset or monitor disease progression has become commonplace. A biomarker precisely reflecting the inflammatory and degenerative components of MS would allow for therapies to be exactly adapted, reducing delays in treatment optimization. The call for robust molecular and cellular biomarkers to evaluate MS therapies is more urgent than ever.

This Special Issue focuses on enhancing our understanding and advancing the field of MS through innovative research on biomarkers. We are inviting original research articles and reviews that explore: Pharmacogenomics and Proteomics in MS, Systems Biology in MS, Omics Association Analysis in MS and Clinical Development of MS Biomarkers.

Guest Editor

Dr. Majid Ghareghan





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)